117 related articles for article (PubMed ID: 34941995)
1. Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy.
Dahiya S; Luetkens T; Lutfi F; Avila S; Iraguha T; Margiotta P; Hankey KG; Lesho P; Law JY; Lee ST; Baddley J; Kocoglu M; Yared JA; Hardy NM; Rapoport AP; Atanackovic D
Blood Adv; 2022 Jan; 6(2):686-689. PubMed ID: 34941995
[No Abstract] [Full Text] [Related]
2. Cellular and humoral immune responses to SARS-CoV-2 vaccination in patients after CD19.CAR T-cell therapy.
Reimann H; Kremer AN; Blumenberg V; Schmidt K; Aigner M; Jacobs B; Eisenhauer N; Kämpf A; Rösler W; Kharboutli S; Mougiakakos D; Lang V; Lischer C; Irrgang P; Leppkes M; Gonzalez JV; Krönke G; Kremer AE; Tenbusch M; Bruns H; Harrer T; Müller F; Schett G; Mackensen A; Subklewe M; Völkl S
Blood Adv; 2023 May; 7(10):2066-2069. PubMed ID: 36206194
[No Abstract] [Full Text] [Related]
3. Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients.
Wu X; Wang L; Shen L; He L; Tang K
J Hematol Oncol; 2022 Jun; 15(1):81. PubMed ID: 35710431
[TBL] [Abstract][Full Text] [Related]
4. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey.
van Doesum JA; Salmanton-García J; Marchesi F; Di Blasi R; Falces-Romero I; Cabirta A; Farina F; Besson C; Weinbergerová B; Van Praet J; Schönlein M; López-García A; Lamure S; Guidetti A; De Ramón-Sánchez C; Batinić J; Gavriilaki E; Tragiannidis A; Tisi MC; Plantefeve G; Petzer V; Ormazabal-Vélez I; Marques de Almeida J; Marchetti M; Maertens J; Machado M; Kulasekararaj A; Hernández-Rivas JÁ; Gomes da Silva M; Fernández N; Espigado I; Drgoňa Ľ; Dragonetti G; Metafuni E; Calbacho M; Blennow O; Wolf D; van Anrooij B; Nunes Rodrigues R; Nordlander A; Martín-González JA; Liévin R; Jiménez M; Gräfe SK; García-Sanz R; Córdoba R; Rahimli L; van Meerten T; Cornely OA; Pagano L
Blood Adv; 2023 Jun; 7(11):2645-2655. PubMed ID: 37058479
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 Vaccination and Anti-CD19 CAR T Cell-Induced B Cell Aplasia.
Sookaromdee P; Wiwanitkit V
Transplant Cell Ther; 2022 Aug; 28(8):515. PubMed ID: 35598839
[No Abstract] [Full Text] [Related]
6. SARS-CoV-2 vaccine response in CAR T-cell therapy recipients: A systematic review and preliminary observations.
Abid MA; Abid MB
Hematol Oncol; 2022 Apr; 40(2):287-291. PubMed ID: 34911142
[TBL] [Abstract][Full Text] [Related]
7. On a collision course: SARS-CoV-2 variants and CAR T cells.
Auletta JJ
Blood Adv; 2023 Jun; 7(11):2643-2644. PubMed ID: 37310762
[No Abstract] [Full Text] [Related]
8. Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy.
Dhakal B; Abedin S; Fenske T; Chhabra S; Ledeboer N; Hari P; Hamadani M
Blood; 2021 Oct; 138(14):1278-1281. PubMed ID: 34339501
[No Abstract] [Full Text] [Related]
9. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
[TBL] [Abstract][Full Text] [Related]
10. B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19.
Zollner A; Watschinger C; Rössler A; Farcet MR; Penner A; Böhm V; Kiechl SJ; Stampfel G; Hintenberger R; Tilg H; Koch R; Antlanger M; Kreil TR; Kimpel J; Moschen AR
EBioMedicine; 2021 Aug; 70():103539. PubMed ID: 34391087
[TBL] [Abstract][Full Text] [Related]
11. Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy.
Marty PK; Van Keulen VP; Erskine CL; Shah M; Hummel A; Stachowitz M; Fatis S; Granger D; Block MS; Duarte-García A; Warrington KJ; Theel ES; Zhou X; Zeng H; Specks U; Escalante P; Peikert T
Front Immunol; 2022; 13():834981. PubMed ID: 35154159
[TBL] [Abstract][Full Text] [Related]
12. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
Front Immunol; 2021; 12():726960. PubMed ID: 34671348
[TBL] [Abstract][Full Text] [Related]
13. TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma.
Noh KE; Lee JH; Choi SY; Jung NC; Nam JH; Oh JS; Song JY; Seo HG; Wang Y; Lee HS; Lim DS
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445415
[TBL] [Abstract][Full Text] [Related]
14. Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients.
Schietzel S; Anderegg M; Limacher A; Born A; Horn MP; Maurer B; Hirzel C; Sidler D; Moor MB
RMD Open; 2022 Feb; 8(1):. PubMed ID: 35115385
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
Front Immunol; 2021; 12():690698. PubMed ID: 34276681
[TBL] [Abstract][Full Text] [Related]
16. Response to: Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli
Bonelli M; Aletaha D
Ann Rheum Dis; 2021 Oct; 80(10):e167. PubMed ID: 34340982
[No Abstract] [Full Text] [Related]
17. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.
Dai H; Wu Z; Jia H; Tong C; Guo Y; Ti D; Han X; Liu Y; Zhang W; Wang C; Zhang Y; Chen M; Yang Q; Wang Y; Han W
J Hematol Oncol; 2020 Apr; 13(1):30. PubMed ID: 32245502
[TBL] [Abstract][Full Text] [Related]
18. Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli
Chung SH; Wener M; Bays AM; Rahbar H; Morishima C; Bryan AB; Fink SL; Cohen S; Mani NS; Chaudhary A; Gardner GC
Ann Rheum Dis; 2021 Oct; 80(10):e165. PubMed ID: 34340981
[No Abstract] [Full Text] [Related]
19. Response to: 'Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'' by Westhoff
Bonelli M; Aletaha D
Ann Rheum Dis; 2021 Oct; 80(10):e163. PubMed ID: 34272251
[No Abstract] [Full Text] [Related]
20. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
